National Cancer Institute (NCI): Squamous Cell Carcinoma of Head and Neck trials

The registry lists 60 Squamous Cell Carcinoma of Head and Neck studies with National Cancer Institute (NCI) as lead sponsor. 8 are open to participants now and 22 have results posted.

Phase 1 27Phase 2 38Phase 3 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruitingNCT07667400Phase 1/2
• Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT07156227Phase 1
• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerRecruitingNCT06980038Phase 2
• Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruitingNCT06589804Phase 3
• Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerRecruitingNCT06223568Phase 2
• Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT06161545Phase 2
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 2
• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT04671667Phase 2
• Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal CancerActive, not recruitingNCT05996523Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingNCT04576091Phase 1Results posted
• De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal CancerActive, not recruitingNCT03952585Phase 2/3Results posted
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinCompletedNCT03258554Phase 2/3Results posted
• ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive TreatmentTerminatedNCT02917629Phase 2Results posted
• Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck CancerActive, not recruitingNCT02567422Phase 1Results posted
• Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck CancerTerminatedNCT02196168Phase 2Results posted
• Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing SurgeryCompletedNCT02007200Phase 2Results posted
• Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck CancerCompletedNCT01711541Phase 1/2Results posted
• Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by SurgeryCompletedNCT01696955Phase 2Results posted
• Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by SurgeryActive, not recruitingNCT01468896Phase 1/2Results posted
• Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerTerminatedNCT01267240Phase 2Results posted
• Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous TherapyCompletedNCT01256385Phase 2Results posted
• Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabCompletedNCT00939627Phase 2Results posted
• Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT00588770Phase 3Results posted
• Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00513435Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00507767Phase 2Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00387335Phase 2Results posted
• Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00103259Phase 2Results posted
• SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00095628Phase 2Results posted
• Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00084682Phase 2Results posted
• Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnNCT05879484Phase 1/2
• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT05172258Phase 2
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell CarcinomaCompletedNCT02775812Phase 1
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and CisplatinCompletedNCT02381535Phase 1
• Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck CancerCompletedNCT01935921Phase 1
• Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerSuspendedNCT01810913Phase 2/3
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedNCT01727076Phase 1
• Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck CancerCompletedNCT01254617Phase 1
• Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00906360Phase 1
• Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck CancerCompletedNCT00458978Phase 2
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00114283Phase 2
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00098631Phase 2
• S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00081211Phase 1
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckCompletedNCT00063895Phase 1/2
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00055913Phase 1/2
• Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck CancerCompletedNCT00055770Phase 1/2
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00049283Phase 1
• Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and NeckCompletedNCT00033618Phase 2
• Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck CancerTerminatedNCT00033449Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1